Tuesday, October 13, 2026

Plug Power Stock Over 10% Down Today

November 17, 2020

Shares of Plug Power slid by a staggering 10.22% to $22.44 at 19:05 UTC on Tuesday. The Nasdaq Stock Market rose by 0.14% to $11941.2. This was the stock's two sequential sessions of gains. Plug Power closed at $18.86, below its 52-week high of $19.1. Plug Power's sales growth is 79% for the present quarter and a decline by 4.5% for the next. The company's growth estimates for the current quarter is 22.2%. Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 260.01M for the twelve trailing months. Plug Power's stock is valued at $22.44, way higher than its 52 Week High of 19.1. Plug Power's worth is way above its 50 day moving average of $15.38. Plug Power's value is way higher than its 200 day moving average of $9.91.

Tags

Stock Market Stock Wall Street Stock Price Stock Market Now NASDAQ Market Session IXIC The Nasdaq Stock Market Plug Power PLUG

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,372 source documents archived

Query this data → isubstrate.com

Categories

Tags